tiprankstipranks
Blurbs

Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN), SAGE Therapeutics (SAGE) and Moderna (MRNA)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on BioMarin Pharmaceutical (BMRNResearch Report), SAGE Therapeutics (SAGEResearch Report) and Moderna (MRNAResearch Report).

BioMarin Pharmaceutical (BMRN)

In a report released yesterday, Akash Tewari from Jefferies maintained a Buy rating on BioMarin Pharmaceutical, with a price target of $100.00. The company’s shares closed last Wednesday at $88.40.

According to TipRanks.com, Tewari is a 4-star analyst with an average return of 17.8% and a 61.9% success rate. Tewari covers the Healthcare sector, focusing on stocks such as Arvinas Holding Company, Enanta Pharmaceuticals, and Horizon Therapeutics.

BioMarin Pharmaceutical has an analyst consensus of Strong Buy, with a price target consensus of $110.00, implying a 26.5% upside from current levels. In a report issued on August 1, J.P. Morgan also initiated coverage with a Buy rating on the stock with a $140.00 price target.

See today’s best-performing stocks on TipRanks >>

SAGE Therapeutics (SAGE)

In a report released today, Douglas Tsao from H.C. Wainwright maintained a Hold rating on SAGE Therapeutics, with a price target of $55.00. The company’s shares closed last Wednesday at $36.02.

According to TipRanks.com, Tsao is a 2-star analyst with an average return of 0.0% and a 37.7% success rate. Tsao covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Cerevel Therapeutics Holdings, and Praxis Precision Medicines.

Currently, the analyst consensus on SAGE Therapeutics is a Moderate Buy with an average price target of $54.54, representing a 54.8% upside. In a report issued on August 2, RBC Capital also maintained a Hold rating on the stock with a $37.00 price target.

Moderna (MRNA)

In a report released yesterday, Michael Yee from Jefferies maintained a Hold rating on Moderna, with a price target of $170.00. The company’s shares closed last Wednesday at $186.49.

According to TipRanks.com, Yee is a 1-star analyst with an average return of -3.0% and a 40.8% success rate. Yee covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, LianBio Sponsored ADR, and Olema Pharmaceuticals.

Moderna has an analyst consensus of Moderate Buy, with a price target consensus of $212.10, implying a 26.4% upside from current levels. In a report issued on August 1, J.P. Morgan also initiated coverage with a Hold rating on the stock with a $165.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on BMRN:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More